– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated...
WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory...
WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory...
– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and...
– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned...
Barchart Research What to Expect from UPB Earnings UPB Generated May 11, 2026 Current Price $9.11 EPS Estimate $$-0.80 Consensus Rating Strong Buy Average Move 5.12% Upstream Bio's VALINAT Data Could Redefine...
Barchart Research What to Expect from UPB Earnings UPB Generated May 4, 2026 Current Price $9.31 EPS Estimate $$-0.78 Consensus Rating Strong Buy Average Move 5.12% Upstream Bio's Verekitug Data Will Either...
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. Â (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory...
– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – –...